Pidilizumab clinical trials
Also written CT-011 and MDV9300.
How each study uses pidilizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pidilizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 7
Medivation, Inc. (3) · CureTech Ltd (3) · Augusta University (2) · M.D. Anderson Cancer Center (1) · CARsgen Therapeutics Co., Ltd. (1) · Ohio State University Comprehensive Cancer Center (1) · Northwestern University (1) · Hadassah Medical Organization (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pidilizumab.
- Dec 2026CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionPhase 1 · CARsgen Therapeutics Co., Ltd.
Studies
Open first, then newest update. How each study uses pidilizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingPhase 1CARsgen Therapeutics Co., Ltd.NCT06560827Written as CT011 CAR-GPC3 T Cells InjectionHow we know
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1Ohio State University Comprehensive Cancer CenterNCT02077959Written as pidilizumabHow we know
- Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate CancerTerminatedPhase 2Augusta UniversityNCT01420965Written as CT-011 (Anti-PD1 Antibody)How we know
- Gemcitabine and CT-011 for Resected Pancreatic CancerTerminatedPhase 2Augusta UniversityNCT01313416Written as CT-011How we know
- Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First RemissionTerminatedPhase 2Northwestern UniversityNCT02530125Written as PidilizumabHow we know
- CT-011 and p53 Genetic Vaccine for Advanced Solid TumorsWithdrawnPhase 1National Cancer Institute (NCI)NCT01386502Written as CT-011How we know
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnPhase 2Medivation, Inc.NCT02653989Written as MDV9300How we know
- Anti PD1 Antibody in Diffuse Intrinsic Pontine GliomaStatus unknownPhase 1/2Hadassah Medical OrganizationNCT01952769Written as MDV9300How we know
- Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00904722Written as CT-011How we know
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic MelanomaCompletedPhase 2Medivation, Inc.NCT01435369Written as CT-011How we know
- Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX AloneCompletedPhase 2Medivation, Inc.NCT00890305Written as CT-011How we know
- CT-011 MAb in DLBCL Patients Following ASCTCompletedPhase 2CureTech LtdNCT00532259Written as CT-011How we know
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I InfectionTerminatedPhase 1/2CureTech LtdNCT00962936Written as CT-011How we know
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular CarcinomaTerminatedPhase 1/2CureTech LtdNCT00966251Written as CT-011How we know
Given beside what is tested · 2 — pidilizumab is usual care or a partner of the new treatment
- Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell TransplantationCompletedPhase 2Beth Israel Deaconess Medical CenterNCT01067287Written as CT-011How we know
- PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell VaccineTerminatedPhase 2Beth Israel Deaconess Medical CenterNCT01441765Written as CT-011How we know
Codes
What other systems call pidilizumab · ClinicalTrials.gg INT006415
- MeSH (NLM) C585832pidilizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) B932PAQ1BQPIDILIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7191298pidilizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71014PidilizumabOne source FDA
- DrugBank DB15383One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585832 | pidilizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | B932PAQ1BQ | PIDILIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7191298 | pidilizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71014 | Pidilizumab | One source FDA |
| DrugBank | DB15383 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.